Cited by 12Lipoproteins and Cardiovascular HealthBlood Pressure and Hypertension StudiesCholesterol and Lipid Metabolism

The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With Pravastatin: Main Results of the APPROACH-J Study

Open access
Daida, Hiroyuki, Teramoto, Tamio, Kitagawa, Yasuhisa, Matsushita, Yasuyuki, Sugihara, Masahiro, APPROACH-J Study Group·2014·International Heart Journal

Abstract

This study aimed to evaluate the relationship between low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular disease (CVD) in high-risk patients with hypercholesterolemia without a history of CVD. Patients who were receiving or started treatment with pravastatin, were followed-up for 2 years. Patients were divided into quartiles according to on-treatment LDL-C. The maximum contrast method based on the Cox proportional hazards model was used to evaluate the relationship between achieved LDL-C and the incidence of CVD. Incidence of CVD was also compared according to whether a number of risk factor targets were achieved. A total 6,229 patients were enrolled, with 4,916 having reported LDL-C values. During the 2 years, 69 cases of CVD (6.7/1000 patient years), including 36 coronary artery disease (CAD) (3.5/1000 patient years) and 28 strokes (2.7/1000 patient years), occurred. The comparison of on-treatment LDL-C level quartiles suggested that the incidence of all CVD decreased linearly as the LDL-C levels decreased. Incidence of CAD showed a curvilinear relationship to LDL-C levels, suggesting some attenuation of risk below LDL-C of 119 mg/dL. The incidence of all CVD and CAD tended to be decreased as the number of achieved risk factor targets increased. In conclusion, through our observational study, it was shown that a linear relationship between the incidence of CVD and LDL-C was observed in high-risk hypercholesterolemic patients. The low incidence of CVD in the present study may be associated with multifactorial management of conventional risk factors including high LDL-C levels. However, prospective, randomized studies are needed to confirm these findings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1536/ihj.13-002

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The effectiveness of statins for preventing the first occurrence and recurrence of stroke in Japanese populations was confirmed in a sub-analysis of the MEGA study and in the JELIS study.

    “The effectiveness of statins for preventing the first occurrence and recurrence of stroke in Japanese populations was confirmed in a sub-analysis of the MEGA study620, 621) and in the JELIS study622).”
  • The results of a sub-analysis of JELIS showed that treatment with statins and EPA in patients with a stroke history significantly suppressed the recurrence of stroke by approximately 20% compared with statin monotherapy.

    “The results of a sub-analysis of JELIS showed that treatment with statins and EPA in patients with a stroke history significantly suppressed the recurrence of stroke by approximately 20% compared with statin monotherapy622).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 47 · Cited by 12

Research works printed but not linked: 5

  1. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to pre- vent cardiovascular events in men and women with elevated C-re- active protein. N Engl J Med 2008; 359: 2195-207.
  2. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorv- astatin on early recurrent ischemic events in acute coronary syn- dromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
  3. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Ja- pan Atherosclerosis Society (JAS) guideline for diagnosis and pre- vention of atherosclerotic cardiocardiovascular diseases for Japa- nese. J Atheroscler Thromb 2007; 14: 45-50. (Review)
  4. Haria M, McTavish D. Pravastatin. A reappraisal of its pharmaco- logical properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53: 299-336. (Review)
  5. Peto R, Peto J. Asymptotically effi cient rank invariant test proce- dures. J R Stat Soc Ser A 1972; 135: 185-207.

Authors
Daida, H., Teramoto, T., Kitagawa, Y., Matsushita, Y., Sugihara, M., & APPROACH-J Study Group
Affiliations
  • Juntendo University (JP)
  • Teikyo University (JP)
  • Tokai University Hachioji Hospital (JP)
  • Daiichi-Sankyo (Japan) (JP)
Venue
International Heart Journal
Published
2014
Volume
55
Issue
1
Pages
39-47
ISSN
  • 1349-2365 (ISSN-L)
  • 1349-3299
OpenAlex
W1903851753
Cited by
12
References
47
Citations by year
2026: 1 · 2023: 1 · 2021: 2 · 2018: 2 · 2017: 3 · 2016: 3
FWCI
1.98
Type
journal article
Language
en
Open access
Locations
  • International Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Daiichi-Sankyo
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
LDL cholesterol, pravastatin, cardiovascular disease incidence, hypercholesterolemia, coronary artery disease, stroke, statin therapy, LDL cholesterol targets, risk factor control, high-risk patients
MeSH terms
Aged, Female, Humans, Hypercholesterolemia, Japan, Cholesterol, LDL, Male, Middle Aged, Prospective Studies, Incidence, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review